 Cassa va Science s, Inc. Clinical Prot ocol PTI -125-04 
Simufilam  (PTI-125), A small molecul e to treat AD June 11, 2021 
 
Amendme nt #7   Page 1 of 39     CON FIDENTIAL  
 
7801 N. Capital of Texas Hwy, Ste. 260  
Austin, TX 78731  
CLINICAL  RESEARCH  PROTOCOL  
PROTOCOL  PTl-125-04 
 
A 12 -Month , Open -Label Safety  Study  of Simufilam followed by  a 
6-Month Randomized Withdrawal and 6 Additional  Month s 
Open-Label in Mild-to-moderate Alzheimer’s Disease  Patients  
 
Sponsor:      Cassava Scienc es, Inc. 
7801 N. Capital  of Texas Hwy, Ste. 260  
Austin, TX 78731  
 
Program Lead:   Lindsay H. Burns, PhD  
 SVP, Neur oscience  
 Phone:     512-501-2484  
 Email:      lburns@cassavasci ences.com  
 
Study  Monitor : Nadav Fr iedmann , PhD, MD  
Chief Operating & Medical Officer  
Phone:  925-788-4585  
Email: nfriedman n@cassavasciences .com  
 
Project Manager  Ben J. Murray  
 Sr. Clinical Project Manager   
 Phone:    512-501-3180  
 Email:     bmurray @cassava sciences.com  
 
Protocol  Date: February 1 0, 202 0 
Amendment # 1 March 17, 2020  
Amendment #2  April 02, 2020  
Amendment #3  May 6, 2020 
Amendment #4  October 28, 2020  
Amendment #5  December 3 0, 2020  
Amendment #6  Feb 8 , 2021  
Amendment #7  June  11, 2021  
 
This clinical  trial is  support ed by NIH grant AG 065152.  
Confidentiali ty: The information  contained in this document  and all infor mation 
provided  to you relate d to simufilam  ("Study Drug") are the confidential  and propri etary 
information  of Cassava Scien ces and excep t as may be required  by federal,  state,  or local 
laws or regulati ons, may not be disclosed to others without  prior  writte n permission  of 
Cassava . The Principal  Investigator  may,  however,  disclose  such informati on to 
supervised  individuals  work ing on the Drug,  provided  such individuals  agree  to be 
bound to maintain  the confid entiality  of such Drug  information.  
 Cassa va Science s, Inc. Clinical Prot ocol PTI -125-04 
Simufilam  (PTI-125), A small molecul e to treat AD June 11, 2021 
 
Amendme nt #7   Page 2 of 39     CON FIDENTIAL   
SUMMARY OF PROTOCOL AMENDMENT #7 
 
Approvals:  
Changed:    Carrie Crow ley      
Director, Quality 
Assurance  
Changed to:    Ben J. Murray       
Sr. Clinical Project 
Manager  
Changed t hroughout where vital signs are lis ted: 
• Vital signs (b lood pressure, temperature, pulse and respirato ry rat e) 
Changed to:  
• Vital signs (b lood pressure, temperature, pulse and respiratory rat e), and weight 
 
4. SUMMA RY OF STUDY DESIGN  
 
Changed : approximately 150 patients  
Changed to:  up to 200  patients 
Added to list of Day 1 activit ies: and the C -SSRS.  
Chang ed: PK blood  samples  will be obtained  in the morning  before dosing at  all 
retur n visits  except Months 4.5, 7.5  and 10.5.  
Changed to : PK blood  samples  will be obtai ned in the morning  before dosing at 
return visits  on Months 15 and 18.  
5.1 STU DY POPULATION  
Changed:  Between  100 and 150 patients  will be enrolled  
Changed t o: Up to  200 patients  will be enrolled  
5.3 Exclusion Criteria  
Changed  29, 30 , 31, 32, 33 : Prior to randomi zation  
Changed to: Prior to enrollment  
Changed  41: Loss of significan t volume of bloo d (>450 mL) wit hin 4 weeks prior t o 
the study  
 Cassa va Science s, Inc. Clinical Prot ocol PTI -125-04 
Simufilam  (PTI-125), A small molecul e to treat AD June 11, 2021 
 
Amendme nt #7   Page 3 of 39     CON FIDENTIAL  Changed to: Loss of significan t volume of blood (>450 mL) wit hin 4 weeks prior to 
enrollment  
Changed  42: COVID -19 infection with in 3 months  
Change d to: COVID -19 infection within 3 months of screening  
7.2.1 Screening Visit 1  (days -29 to 0)  
Added :   Confirmation that the patient is either fully vaccinated  for the COVID -19 
virus at leas t 2 weeks prior to first dose of simufil am, or a positive  serol ogy test for the 
COVID -19 virus  with no current symptoms  
7.2.4 Follow-up Visits on Mon ths 1, 3, and 9, 13, 15 and 21  
 
Changed:  Within 30 min  prior to dosing,  the following  assessments  will be 
conducted:  
• Blood sample  collection  for PK assessment (for C min) 
Changed to:  Within 30 min  prior  to dosing,  the following  assessment s will be 
conducted:  
• Blood sample  collection  for PK assessment (for C min – Month 15 only) 
Changed : Cheek swab  for genetic testing  Month 15 Visit only 
Changed to:  Saliva collection  for gene tic testing  Month 15 Visit only 
7.2.5 Follow -up Visit on Month  2 
Deleted: Blood sample  collection  for PK assessment (for C min) 
 
7.2.6 Follow -up Visits on Mon ths 4.5, 7.5, and 10.5  
Changed:   Patients  will return to clin ic at an y tim e of day  
Changed to:   Patients will return to clin ic at an y tim e of day . The visit may be 
conducted by telemedicine , based on the judgement of the Investigator  
 
7.2.7 Follow-up Visit on Mon th 6 and 18  
Changed : Blood sample  collection  for PK assessment (for C min) 
Changed to:  Blood sample collection  for PK assessment (for Cmin – Month 18 
only) 
 Cassa va Science s, Inc. Clinical Prot ocol PTI -125-04 
Simufilam  (PTI-125), A small molecul e to treat AD June 11, 2021 
 
Amendme nt #7   Page 4 of 39     CON FIDENTIAL  Move d from After Dose  to Within 30 min prior to dosing : Plasm a sample  collec tion (from 
8 mL whole blood ) for Sava Dx and other  plasma biomarkers. 
7.2.8 Follow -up Visit on Month 12  and 24  
Added fo r clarity: Month 12  morning dose in the  clinic will be from Open -Label 
Period 1 bottle.  Month 12 eve ning do se will be fro m the Randomized Period 2 bottle . 
Deleted: Blood sample  collection  for PK assessment (for C min) 
Moved from After Dose  to Within 3 0 min  prior to dosing : Plasm a sample  collec tion (from 
8 mL whole blood ) for Sava Dx and other  plasma biomarkers. 
7.3.2 Preparati on of  Plasma Samples for Lymphocyte and Plasma Biomarker  Deter mination  
Added : These  patients with prior  samples shipped as  whole  blood will continue to 
have samples shipped as whole blood only through  Mont h 12. Samples at Months 
15, 1 8, 21 and 24 will be spun to  plasma . 
7.3.3 Preparati on of  Plasma Samples for P harmaco kinetic Determination  
Change d: At each blood  collection for PK (pre-dose sa mples for Cmin at all visits  
except Months 4. 5, 7.5 and 10.5 ),  
Changed to:  At each blood  collection  for PK (pre-dose samples for Cmin at Months 15  
and 18 only ),  
7.3.5  Collection of Chee k Swab Saliva Samples for Genetic Testing  
Entire sec tion ch ange d fro m: Cheek swab  saliva samples wil l be collect ed only at 
Month 1 5. Patients will refrain from eating or drinki ng 1 h prior to saliva collection. 
Each patient  will be instructed to pla ce a standar d 2" × 2"  piece of cotton gauze in the 
buccal region o f their c heek for 3 mi n. The saliva -saturated cotton spit wad will be 
removed, rolled to fit a collect ion tube, and s tored  at -20°C until instructed to ship by 
the Sponsor.  
Changed to:  Saliva samples wil l be collect ed only at Month 15.  Patient s will refrai n 
from eating or drinkin g 1 h prior to saliva collection. Ea ch patient  will be instructed to 
spit into a saliva collection tube . The sa liva will be stored at -20°C until instructed to 
ship by the Sponsor.  
8. EARLY DI SCONTINUATION  
Changed: Patients who d iscontinue will not be replaced. 
Changed to: Patients who d iscontinue may be replaced at Sponsor discretion.  
 Cassa va Science s, Inc. Clinical Prot ocol PTI -125-04 
Simufilam  (PTI-125), A small molecul e to treat AD June 11, 2021 
 
Amendme nt #7   Page 5 of 39     CON FIDENTIAL  9.5 SERIOUS ADVERSE EVENTS REPORTING  
Added : or notification via email  through the ED C system  
10.2 PHAR MACOKINETIC  ANAL YSIS 
Changed : The only plasma P K pa ramete rs to be collected  from this study are the Cmin 
values from blood sam ples tak en prior to dosing  on Mon ths 1,  2, 3 and 9, as well as the 
sample on  Mont h 6 or 12 colle cted just after  the CSF draw  (taken only if undergoin g a 
CSF draw). 
Changed to:  The only pl asma PK parameters t o be collected  from this study are the 
Cmin values from blood sam ples tak en prior to dosing  at Months 15 and 18 . 
10.5 PHAR MACOKINETIC  ANAL YSIS 
Changed:  Between 100 and 150  patients 
Changed to:  Up to 200  patients 
15. APPENDIX A   
 
Event s chedule has b een updated  to reflect PK samples taken only at 
Months 15 and 18  and addition of weight when vital signs are taken . 
Modifie d footnote “a” to state  patients should be reconsented at their 
next study visit.  Additionall y, a notation is  mad e to o mit drug 
dispe nsation at Month 24.  
 Cassa va Sciences , Inc.  Clinica l Protocol PTI-125-04 
Simufilam (PTI-125), A small m olecule to treat  AD June 11 , 2021 
 
Amendme nt #7   Page 7 of 39     CON FIDENTIAL   
Cassava Sciences, Inc. 
CLIN ICAL RESEARCH  PROTOCOL  
 
 
 
 
A 12 -Month , Open-Label Safety Study  of Simufil am followed  by 
a 6-Month Randomized Withdrawal a nd 6 Additional  Month s 
Open-Label in Mild-to-moderate  Alzheimer ’s Disease  Patients  
 
 
 
Signat ure of Agreement  for Protocol  PTI-125-04 
Amend ment #7 
 
 
 
I have read this protocol and agree to conduct  the study as outlined herein,  in 
accordance  with Good  Clini cal Practice (GCP)  and comp lying  with the obligati ons 
and requireme nts of clinical investig ators  and all other requirement s listed in 21 
CFR part 312. 
 
 
 
 
   
Principal Inves tigator  Signature  Date  
 
 
 
 
  
Print Principal Investigator Name and Title  
 
 Cassava  Science s, Inc.  Clinical Protocol PTI -125-04 
Simufilam (PTI-125), A small mole cule to treat  AD June 1 1, 2021 
Amendme nt #7   Page 8 of 39     CON FIDENTIAL  TABL E OF CONTEN TS 
1. List of abbr eviations  ................................ ................................ ...............................  10 
2. INTRODUCTION  ................................ ................................ ................................ .. 12 
2.1. Mechanism of Action  ................................ ................................ ................................ ..... 12 
2.2. Safet y pharmacology and toxicology  ................................ ................................ ...............  12 
2.3. Clinical Studies  ................................ ................................ ................................ .............  13 
2.3.1.  A first -in-human Single Ascending Dose clinical tria l ................................ ........  13 
2.3.2.  First-in-patient multidose linical trial in mild -to-moderate AD patients  ...............  13 
2.3.3.  Double -blind placebo -controlled clinical trial in mi ld-to-moderate AD patients .. 14 
2.3.4.  Open -label safety clinical trial in mild -to-moderate A D patients  ........................  15 
3. STUDY  OBJECTIVES  ................................ ................................ .............................  16 
4. SUMMARY OF STUDY DESIGN  ................................ ................................ ..........  16 
5. SUBJECT SELECTION  ................................ ................................ ...........................  17 
5.1. Study Populatio n ................................ ................................ ................................ ...........  17 
5.2. Inclusion Criteria  ................................ ................................ ................................ ...........  17 
5.3. Exclusion Criteria  ................................ ................................ ................................ ..........  18 
6. STUDY  DRUG ................................ ................................ ................................ ...... 20 
6.1. Study Drug Physical Description and Preparation  ................................ .............................  20 
6.1.1. Storage  ................................ ................................ ................................ ..............  21 
6.1.2.  Drug Accountability  ................................ ................................ ............................  21 
6.2. Administration  and Dosing  Regimen  ................................ ................................ .............  21 
6.3. Concomitant  Medications  ................................ ................................ ................................  21 
7. STUDY  PROCEDURES ................................ ................................ ...........................  21 
7.1. stopping criteria  ................................ ................................ ................................ .............  21 
7.2. Evaluations by Visit  ................................ ................................ ................................ ....... 22 
7.2.1.  Screening Visit 1 (Day s -29 to 0)  ................................ ................................ ....... 22 
7.2.2.  Screening  Visit 2 (Days -28 to 0)  ................................ ................................ ........  23 
7.2.3.  Study Day 1   (Dosing Initiation)  ................................ ................................ .........  23 
7.2.4.  Follow -up Visits on Months 1, 3, 9, 13, 15, 21  ................................ ...................  24 
7.2.5. Follow -up Visit o n Month 2  ................................ ................................ ................  24 
7.2.6.  Follow -up Visits on Months 4.5, 7.5 and 10.5  ................................ ....................  25 
7.2.7.  Follow -up Visits on Month 6 and 18  ................................ ................................ ... 25 
7.2.8.  Month 12 and 24 Follow -up Visits  ................................ ................................ ...... 26 
7.2.9 . Withd rawal Day 1 Visit – If Needed  ................................ ................................ ... 27 
7.3. Laboratory Assessments  ................................ ................................ ................................ . 27 
 Cassava  Science s, Inc.  Clinical Protocol PTI -125-04 
Simufilam (PTI-125), A small mole cule to treat  AD June 1 1, 2021 
Amendme nt #7   Page 9 of 39     CON FIDENTIAL  7.3.1.  Clinical  Laboratory  Tests  ................................ ................................ ....................  27 
7.3.2.  Preparation  of Whole Blood  Samples  for Lymphocyte and Plasm a Biomarkers  28 
7.3.3.  Preparation  of Plasma  Samples  for Pharmacokinetic  Determination  ..................  28 
7.3.4.  Preparation of CSF samples  ................................ ................................ ..............  28 
7.3.5.  Collection of Cheek Swab Saliva Samples for Genetic Testing  ........................  28 
8. EARLY  DISCONTINUATION  ................................ ................................ .................  29 
9. ADVERSE  EVENTS/SERIOUS ADVERSE  EVENTS  ................................ .................  29 
9.1. Adverse  Events - Definition  ................................ ................................ ............................  29 
9.2. Adverse Events - Severit y Rating  ................................ ................................ ....................  30 
9.3. Adverse  Events  -  Relationship  to  Study    Drug  ................................ ...............................  30 
9.4. Serious Adverse Events and Unexpected Adverse Events - Definitions  ..............................  31 
9.5. Serious Adverse Events R eporting  ................................ ................................ ..................  32 
10. STATISTICAL  CONSIDERATIONS  ................................ ................................ .........  32 
10.1.  Analysis Populations  ................................ ................................ ................................ ...... 32 
10.2.  Pharmacokinetic Parameters  ................................ ................................ ...........................  33 
10.3.  Statistical Analy sis ................................ ................................ ................................ ........  33 
10.4.  Safety  Analysis  ................................ ................................ ................................ ..............  33 
10.5.  Sample Size  ................................ ................................ ................................ ..................  33 
11. STUDY TERMINATION  ................................ ................................ .........................  33 
12. DATA  COLLECTION,  RETENTION  AND  MONITORING  ................................ ....... 34 
12.1.  Case  Report  Forms  ................................ ................................ ................................ .........  34 
12.2.  Avail ability and Retention of Investigational Records  ................................ .......................  34 
12.3.  Subject Confidentiality  ................................ ................................ ................................ ... 34 
12.4.  Liability  ................................ ................................ ................................ ........................  35 
12.5.  Ethical and Legal Issues  ................................ ................................ ................................ . 35 
12.5.1.  Institutional  Review  Board  ................................ ................................ ..................  35 
12.6.  Informed Consent For m ................................ ................................ ................................ . 36 
13. INVESTIGATOR RESPONSIBILI TIES  ................................ ................................ ... 36 
14. REFERENCES  ................................ ................................ ................................ ...... 37 
15. Append ix A ................................ ................................ ................................ ...........  38 
 
Cassava Sciences, Inc. Clini cal Protocol P TI-125-04 
Simufilam (PTI-125), A small mo lecule to treat AD June 1 1, 2021 
Ame ndment  #7    Page 10 of 39   CON FIDENTIA L 1. LIST OF ABBR EVIATIONS 
7nAChR    7 nicotinic acetylcholine receptor  
A42    amyloid beta 1-42 
AChEI     acety lcholinesterase inhib itor 
AD    Alzheimer’s disease  
ADAS -Cog11   Alzheime r’s Disease Assessment Sca le cognitive  subscale 11  
ADME    absor ption, d istribution, me tabolism, excretion  
ANDI    Alzheimer’s Disease Neuroimaging  Initiative  
AE    adverse e vent 
ALP     alkaline phos phata se 
ALT     alanine  transaminase  
ANOVA    analy sis of variance 
AST     aspartate  transaminas e 
AUC    area under the cu rve 
BUN     blood urea n itrogen 
CFR    Code of Federal Regulations 
Cmin    minimum plasma concentrati on 
Cmax    maximum plasma concentra tion 
CSF    cerebrospinal fluid  
CSI    Cassava Sciences, Inc. 
C-SSRS    Columbia -Suicide Severit y Rating Scal e 
DSMB     Data Saf ety Monitoring Board 
ECG    electrocardiogr am 
eCRF    electronic  case r eport  form  
EDT A    ethyl enediaminetetraacetic acid  
ELISA     enzy me-linke d immunosorbent  assay 
FDA     Federal Drug Association  
FIH    first in human  
FLN A    filamin  A 
GCP     good clinical practic e 
GDS     geriatric depression scal e 
GGT     gamma  gluta myl transpep tidase  
GLP    good laboratory practice  
HBsAg    hepati tis B surface  antigen 
HCV     hepatitis C vir us 
HIV    human immuno deficiency vi rus 
hERG     human ether-a-go-go-related gene 
IB    Inves tigator’s Bro chure 
ICF Informed co nsent form  
ICH Intern ational Coun cil on Harmonizatio n of Technical 
Requirements for Reg istration of Pharmaceuticals  for Human 
Use 
IR    insulin receptor  
IRB    Institutional  Review Board 
Cassava Sciences, Inc. Clini cal Protocol P TI-125-04 
Simufilam (PTI-125), A small mo lecule to treat AD June 1 1, 2021 
Ame ndment  #7    Page 11 of 39   CON FIDENTIA L LDH     lactose dehydrogenase 
LOQ     limit of qu antitation 
MI    myoc ardial infarction  
MMSE     Mini -Mental State Examination 
MRI     magnetic resona nce imagi ng 
mTOR    mam malian target of rapamycin  
NMDA R   N-methyl D -aspartate  receptor  
NOAEL    no ob servable adverse effect level 
NOE L    no ob servable effe ct level 
NfL    neuro filament light chain  
NPI    neurop sychiatr ic invent ory 
OTC     over-the-counter  
PK    pharmac okine tics 
PTI-125   small molecule dr ug candidate to  treat AD  
PTI-125Dx   blood -based d iagnostic/biomarker candidate 
RBC     red blood cell 
SAD     single ascending d ose 
SAE    serious adverse event  
SOP    standard op erating pr ocedure  
TLR4     toll-like recep tor 4 
Tmax    time to C max 
ULN    upper limit  of normal  
WBC     white blood  cell 
YKL40 chitinase-like protein 1, a secreted glycopr otein ass ociated with 
inflammation  and tissue remodeling     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cassava Sciences, Inc. Clini cal Protocol P TI-125-04 
Simufilam (PTI-125), A small mo lecule to treat AD June 1 1, 2021 
Ame ndment  #7    Page 12 of 39   CON FIDENTIA L 2. INTROD UCTION  
2.1. MECHANISM  OF ACTION  
Cassava Scien ces, Inc. is developing  simufil am, a novel drug candidate  designed to treat 
and slow the prog ression of Al zheimer’s  disease (AD). Simufilam  binds wit h femtomolar 
affinity to an altered con formation of filamin A (F LNA ) that is induced by beta amyloid 1-
42 (A42), present in AD brain  and critical to the toxicity of  A42.1-3 Simufilam  binding 
reverses th e altered FLNA conformation  and restores FLNA’s native shape,  preventing 
two t oxic signaling cascades of A 42. A42, in monomer or small oligomer form,  hijack s 
the 7-nicotinic  acetylcholine receptor ( 7nAChR) and signal s via this rec eptor to 
hyperphosphorylate tau . This signaling requires the recruitment of altered  FLNA to this  
receptor. Second, altered FLNA also lin ks to  toll-like receptor 4 (TLR4) to allow A 42 to 
persisten tly activate this receptor. Normal FLNA does not associate w ith either 
7nAChR or TLR4. In addition to disrupting the normal functions of 7nAC hR and tau 
protein , A42’s toxic signaling to hyperph ospho rylate tau leads to the signature tangles 
and plaques in AD brain . In two AD mouse  models and in postmortem h uman AD brain 
tissue, simufilam  restored function of three receptors that are impai red in  AD: the 
7nAChR , the N-methyl -D-aspartate receptor (NMDA R), and the insulin receptor (IR).2,3 
Simufilam  also improved synaptic plasticity  and reduced tau hyperphosphorylation, 
amyloid deposits, neurofibrillary tangles and inflamma tory cytokine release.2,3 We 
therefore expect simufilam  both to improve cognition  and to slow AD progress ion. Both 
mouse models used a dose of 20 mg/kg/day  (equivalent to 6 0 mg/m2/day) .  
2.2. SAFETY PHARMACO LOGY AND TO XICOLOGY  
A robust nonclinical ADME, safety pharmacology, and general and genetic toxicology 
program has been conducted  with simufi lam. In vitro meta bolic profiling showed 
minimal meta bolis m across  several species including  humans. Simufilam  was rapid ly 
absorbed and eliminated in in vivo studies in rat and dog with nearly 100% oral 
bioavailability, a 2.67 -h half -life in dog, dose -proportional PK and no  accumulation. 
Safety pharmacology studi es showed no adverse effects on gro ss behavioral and 
phys iolog ical parameters in the Irwin test of CNS toxicity in rats, no adverse effects on 
respiratory rate, tidal volume or minute volume in the rat respiratory te st, and no adverse 
effects on arter ial b lood press ure, heart rate and ECG p arameters in the dog 
cardio vascular study. The in vitro hERG test for cardiotoxicity also indicated no adverse 
effect. A full battery of genot oxicity studies was c onducted (in vitro  bacterial Ames, in 
vitro chromosom al ab erration, and in vivo rat micronucl eus test) and were all  nega tive. 
An in vitro specificity screen showed no significant activation or inhibition of a panel of 
68 receptors, cha nnels and transporter s.  
 
Cassava Sciences, Inc. Clini cal Protocol P TI-125-04 
Simufilam (PTI-125), A small mo lecule to treat AD June 1 1, 2021 
Ame ndment  #7    Page 13 of 39   CON FIDENTIA L Simufilam  was tested  in single dose and repeat d ose o ral toxicity studies in rats and dog s. 
A 6-month repeat d ose or al toxicity study in rat (PTI-125-NC-049) used the same doses 
as a 28-day study (50, 500 and 1000 mg/kg/day) , which  found 500 mg/kg/day  to be the 
no ob servable adverse effect level ( NOAEL ). In the 6 -month study, t he toxicological  
response was charact erized  by decreased body weights and  adverse structural and 
functional alterations in the liver of 500 and 1000 mg/kg ani mals, including in creased 
weight, hepa tocellular hypertrophy and vacuolat ion, single/multiple basophilic/  
eosinoph ilic/clear cell focus , hepa tocellular degeneration, pigmentation, and oval cell 
hyperplasia. The presence of bile pigment was consistent with cholestasis. These  findings 
correlated  with changes to the clinical chemi stry profile, including increased ALP and  
total/direct bilirub in. Ov er the 1 -month recovery period, there was complete recovery of 
the hepatocellular degeneration and partial recovery  of hepatocellular  hypertrophy.  The 
NOAEL from this 6 -month study was 50 mg/kg /day (equivalent to 300 mg/ m2). A second 
ongoing 6-month repeat  dose oral toxicity study in rat will more accurate ly determine the  
6-month NOAEL  in rat . Doses are vehicle and 125  and 250 mg/kg/day.   
In a 9-month  toxicity study in dog  (PTI-125-NC-050), the no observable effect level 
(NOEL)  of simufilam  was 25 mg/kg. The 200 mg/kg  (high) dose was decreased to 15 0 at 
1 month due to bod yweig ht loss thought unsus tainable for 9 months . Clinical signs were 
saliv ation and a few instances of muscle fascicula tions. There were no pathology 
findings , but the high dose  was co nsider ed adverse d ue to two unexplained d eaths.  The 
75 mg/kg/day NOAEL pro vides 38- and 19 -fold safety mar gins by Cmax and AUC  over 
the 100 m g b.i.d. dose in p atients.  
2.3. CLINI CAL STUDIES  
2.3.1.  A first -in-hum an Single Ascen ding Dose clinica l trial 
A first -in-human, double -blind, Single Ascending Dos e clinical tria l was conducted in 
healthy normal volun teers , age 18 -45 with oral dosing solution . Doses were placebo, 50, 
100 and 200 mg (equivalent to 31, 62,  and 123 mg/m2, respectively)  administered t o three 
differ ent groups of volunteers . The study sho wed dose proportion al PK, and there were 
no drug -related adverse events  (AEs). 
2.3.2.  First -in-patient multidose clinical tr ial in mild-to-moderate AD pati ents 
In a Phase 2a 28-day study , 13 mild-to-moderat e AD patients  receiv ed simufilam  100 m g 
b.i.d. as oral tablets. Patients  were MMS E ≥ 16 and ≤ 24, age 50 -85, with a CSF t otal 
tau/Aβ 42 ratio ≥ 0.30. A se cond CSF sample  was collected on Day 28 , allowing 
assessment of change from baseline in b iomarkers  using commercial  ELISA kits.  All 8 
bioma rkers that are elevated in AD were sig nifica ntly reduced  from baseline  (Fig. 1).4 
Aβ42, which is low in AD, was increased slightly  but non -significantly. Reduced 
inflammatory cyto kines and YKL -40 indicated reduced neuroinfla mmation . A reduced 
neurodegenerative drive was sugg ested by reductions in n eurogranin , neurofilament light 
Cassava Sciences, Inc. Clini cal Protocol P TI-125-04 
Simufilam (PTI-125), A small mo lecule to treat AD June 1 1, 2021 
Ame ndment  #7    Page 14 of 39   CON FIDENTIA L chain,  and total tau. The robust reduction in phospho -tau ( P-Tau181) confirms  the 
mechanism of action of  simufilam . Simufilam  was safe and well tolerated in a ll patients.  
Fig. 1    Phase 2a Mean Change  from Baseline to Day 28  in CSF biomarkers  (±SEM)  
 
2.3.3.  Double -blind placebo -controlled  clinical tr ial in mild-to-moderate AD pati ents 
A Phase 2b  randomized , placebo -control led clinical trial of simufilam  50 or 100 m g 
tablets  or placebo (1:1:1)  enrolled 64  mild-to-moderate AD patients  with MMSE 16-26. 
Both 50 and 100  mg doses significantly improved eleven CSF biomarkers o f AD 
pathology, neurodegeneration, neuroinflammation  and blood -brain barrier  integrity (Fig. 
2). CSF b iomarker analyses  were condu cted blind to treatmen t and timepoint  by an 
outside lab , and s creening and Day 28 samples for each patient were measured in 
triplicate in the same ELISA plate s. Albumin and immunoglobulin G (IgG)  were 
measured by immunob lotting and quanti fied by densitometric quanti tation. Thes e data 
suggest disease modification and replicat e our Phase 2 a results  in a well -controlled study.  
Fig. 2   Phase 2b Mean Change from Baseline to Day 28  in CSF biomarke rs (±SEM)  
 
 

Cassava Sciences, Inc. Clini cal Protocol P TI-125-04 
Simufilam (PTI-125), A small mo lecule to treat AD June 1 1, 2021 
Ame ndment  #7    Page 15 of 39   CON FIDENTIA L The secondary endpoint s in the Phase 2b trial were two cognitive me asures us ing the 
Cambridge Neu ropsychological  Test Automated Battery.  Patients were assessed  on the 
Paired Associ ate Learn ing (PAL) test , measuring  episodic memory, and a test o f spatial 
working memory. The prim ary outcome measures  for each were total erro rs, with errors 
imputed for m ore difficult le vels not rea ched in the PAL test. Simufilam  produced 
encouraging eff ect sizes ( calculated  by He dge’s g for group sizes of 20) , suggesting 
cognitive enhance ment  (Fig. 3). Effect sizes versu s placebo for the test of episo dic 
memory w ere 37% a nd 23% for the 50 and  100 mg groups , respectively, after removing 
the mo st and least  impaired subjects by baseline score. For spati al working memory , 
effect sizes were 17% and 4 6% fo r these respective dose groups.  Cognit ive enhancement 
by simufilam  is supported by preclinical d ata showing improved  function of α7nAChR , 
NMDA R and insulin receptors  and improv ed synaptic plasticity in 3xTg AD  mice  and in 
postm ortem human AD brain  tissue . In both Phase 2 clinical trials, simufilam  was well  
tolerated and no patients discontinued due t o AEs.  
Fig. 3   Phase 2b Mean C hange from Baseline to Day 28  in Total Errors in Mem ory Test  
 
2.3.4.  Open -label safety  clinical tr ial in mild-to-moderate AD pati ents 
We are conducti ng a 1 -year,  open -label safety study in mild -to-moderate  AD patients. 
The study was meant to offer open -label drug to participants of our two Phase 2 studies  
and is also enrolling new patients. In the first 50 patients to reach 6 months , simufilam  
improved  cognition and behavior a t 1, 3 and 6 months . ADAS -Cog11 scores improved 
1.6 points and NP I scores improved  1.3 points from baseline  at 6 months . Mean b aseline 
MMSE was 22.1 , and  mean ADAS -Cog11 was 15.5  for these 50 patients . 

Cassava Sciences, Inc. Clini cal Protocol P TI-125-04 
Simufilam (PTI-125), A small mo lecule to treat AD June 1 1, 2021 
Ame ndment  #7    Page 16 of 39   CON FIDENTIA L 3. STUDY  OBJECT IVES  
The objective s of this study  are to establish 1 -year safety and to  investi gate the effect of 
simufilam  on biomarkers , cogn ition and neuro psych iatric symptoms  during 12 -month  
repeat -dose oral administration  in mild -to-moderat e AD patient s, 50-85 year s of a ge. An 
objective  of the 6 -month randomized with drawal  is to determine whet her mild-to-
moderate A D patie nts, age 50 -85, who have completed a one-year open -label study of 
100 mg b.i. d. simufil am and who continue with active  dosing will s how slower decline on 
ADAS -Cog11 and the NPI than patients  who withdraw from this treat ment . 
4. SUM MARY OF STUDY DESIGN  
The first 12  month s is an open -label treatment  of simufilam 100 mg b.i.d. for pat ients  
who com pleted prior Phase 2 studies PTI-125-02 and PTI-125-03. New patie nts are 
included so that up to  200 patients are enrolled in this stu dy. Month 12 to Month 18 is a 
randomized withdrawal  phase ; patient s will be randomized to continue  taking simufilam  
100 mg b.i .d. or matching placebo. Month 18 to Month 24 will be an a dditional 6 months 
of open -label simufilam 100 mg b.i.d.  Simufilam and p lacebo  will be administered as 
coated oral tablets . Patients who were enrolled prior to this amendment can continue  
upon recon senting to the randomized withdrawal and final  6-month open -label  portio n.    
All patients wil l provid e conse nt to enroll into t his study. Unless patients hav e a p rior 
positive amyloid PET sc an, MRI showing hippocampal v olume loss  or oth er prior  
evidence o f AD , patients will undergo a CSF draw  (if all o ther scr eening criteria are met ) 
to confirm a t otal t au/Aβ42 ratio ≥ 0.28.   
Patient s will report to the clinic in the morning of Day 1 . Prior  to do sing, patients will 
compl ete the following baseline measures : ECG, vital signs, clinical labs , urinalysis , 
listen to he art and lungs , ADAS -Cog11, neuropsychiatric  inventory (NPI), geriatric  
depression scale ( GDS ), and the C-SSRS . A blood sample will be collected  for plasma -
based biomarke rs and genetic testing .  
Patients will return to the clinic every month through Mont h 3 and every 1.5 months 
through Month 12. Visits on Mont hs 4.5, 7.5 and 10.5 will include vital signs, listening to 
heart and lungs, AE monit oring , C-SSRS , and drug dispensation an d accountability only  
and may be conducted by telemedicine , based on the judgement of the Investigator . After 
Mont h 12, visit s will be on Mon ths 13, 15, 18 , 21 and 24.  Patients comple ting Month 12 
prior to availability o f drug supply for the randomized withdrawal  phase will continue 
with active treatment until drug supply is ready and therefore will have an additional  
“Withdrawa l Day 1 ” visit before r esuming w ith the Month 13 visit one month later.  
Cassava Sciences, Inc. Clini cal Protocol P TI-125-04 
Simufilam (PTI-125), A small mo lecule to treat AD June 1 1, 2021 
Ame ndment  #7    Page 17 of 39   CON FIDENTIA L PK blood  samples  will be obtained  in the morning  before dosing at  return visits  on 
Months 15 and 18.  
Blood draws for clinical laboratory tes ting and urine collection  for urinal ysis will be 
performed  at Day 1 and Months 1,  2, 3, 6, 9, 12, 15, 18, 21 and 24 . Safety assessments  of 
vital signs and  listening to heart and lungs  will be conducted at all visits . ECGs  will be 
conducted on Day  1 and Months 1, 3 , 6, 9, 12, 18 an d 24.  
For plasma biomark ers, plasma  samples  will be  collected on Day 1  prior to dosing and on 
Months  3, 6, 9, 12, 15, 18, 21 and 24 . Plasma mark ers include Sava Dx, the 
complementary  diagnostic/bio marker , and a subset of CSF biomar kers (NfL, 
neurogranin , total tau, Aβ42 and Y KL40).  For the fi rst 50 patients who provided a 
screening  CSF sample , an additional CSF sample will be collected at Month 6 or Month 
12 (25 patients each Month 6 and Month 12) . This sample will be use d to asses s CSF 
biom arker changes. These CSF draws will, however, become OPTIONAL  after 50 
patients have provided either a Month 6 or Month 12 CSF sample . Further, these optional 
Month 6 or Month 12  samples should NOT be obtained from  patients who  did not 
provide a CSF sampl e at screening.  
An independ ent Data Safety Monitoring  Board  (DSMB ), will meet perio dically to review  
patie nt safet y assessme nts and determi ne if dosing may contin ue. 
5. SUBJE CT SEL ECTION  
5.1. STUDY POPULATION  
Up to  200 patients  will be enrolled  in the study (male a nd female) .  
5.2. INCLUSION CRITERIA  
All patien ts must comply with the following  Inclusion  Criteria:  
1. Informed consent form (ICF) sig ned by the su bject or l egally acc eptable 
representative. If a legally accepta ble representative signs the IC F, a notation of  
capacity o f the s ubject must b e not ed. 
2. Patien t has a caregiver or legal representative r esponsible for administ ering the drug 
and r ecordi ng the time.  
3. Ages ≥  50 and ≤ 85 years   
Cassava Sciences, Inc. Clini cal Protocol P TI-125-04 
Simufilam (PTI-125), A small mo lecule to treat AD June 1 1, 2021 
Ame ndment  #7    Page 18 of 39   CON FIDENTIA L 4. Clinical diagnosis of demen tia due t o possib le or probable AD consistent with criteria 
established by a workgroup  of the Nati onal Institute on Aging and the Alzheimer's 
Disease Associatio n. 
5. If female,  postmenopausal for at least 1  year 
6. Patien t living at home, senior residential sett ing, or an instit utional setting without  the 
need for continuous (i .e. 24-h) nursing c are 
7. General health status acceptable for participation in the study  
8. Fluenc y (oral and written) in English  or Spanish  
9. If receiving  memantine, rivastigmine, galantamine or an AChEI, receivi ng a stable 
dose for at  least 3 months (90 days) before screening . If receiving d onepezil, 
receiving any dose lower  than 23 mg on ce daily . Mult iple m edications are allowed.  
10. The patient  is a non-smoker for at least 3 years .  
11. The patient or legal representat ive must agree to comply with the drawing of blood 
samples for the PK  assessments , laboratory assessments and SavaDx. 
12. MMSE -2 score ≥  16 and ≤  26 at screening , OR if > 26, must have evide nce of AD 
pathology such as a prior CSF total tau/A β42 ratio ≥ 0.28 , an amyloid positive PET 
scan or hi ppocamp al volume loss consistent with AD .  
5.3. EXCLUSION CRITERIA  
Patients meeting any of  the following Exclusion C riteria will be excluded fr om the stud y: 
1. Anything that in the opinion  of the Investig ator would preclude part icipation i n a 2-
year study . 
2. BMI < 18.5  
3. Positiv e urine drug scre en. 
4. Positive HIV,  HCV  or HbsAg screen . 
5. Suicidality on C -SSRS 
6. Exposure  to an experimental drug  other tha n simufilam , experimen tal biolog ic or 
experimental medical device wit hin 3 months b efore screening  
7. A medical  condition that would inter fere with a lumbar p uncture  
8. Residence in a skilled nursing  facility  and re quiring 24 h ca re. 
9. Clinically significant laboratory test results  
Cassava Sciences, Inc. Clini cal Protocol P TI-125-04 
Simufilam (PTI-125), A small mo lecule to treat AD June 1 1, 2021 
Ame ndment  #7    Page 19 of 39   CON FIDENTIA L 10. Clinically sig nificant untreated hypothyroidism (if treated, th yroid-stimulating 
hormone  level and thyroid suppleme ntation dose must be  stable for at least 6 months 
before sc reening)  
11. Insuffi ciently control led diabetes mellitus , including requiring insulin or  metformin  
>1000 mg/day.  
12. Renal insufficiency (serum creatinine >  ULN and clinically sig nificant in the opinion 
of PI and/or Sponsor  OR eGFR <60 ml/min/m2 as estimated by  either the MDRD or  
CKD-EPI equation ) 
13. Malignant tumor within 3 years before screening  (except squamous and b asal cell 
carcinoma or ce rvical carcinoma in situ or localized prostate cancer  or localized stage 
1 bladder cancer ) 
14. History of ischemic coli tis or i schemic enterocolit is 
15. Unstable medic al condition that is clinically significant in th e judgment of the 
inves tigator  
16. Alanine transamin ase (ALT) or aspartate transaminase (AST) > ULN  or total 
bilirubin > ULN  and clinically sign ificant in the opinion of PI and/or Sponsor .  
17. History of myocardial infarction or unstable ang ina within 6 months befo re screening  
18. History of more than 1 myocardial  infarction wit hin 5 years before screening  
19. Clinically significant  cardiac arrhythmia (inclu ding atrial fibrillatio n), 
cardiomyopathy, or card iac conduction def ect (patients  with a pacem aker are 
acceptable)  
20. Symptomatic hyp otension,  or uncontrolled hyperten sion  
21. Clinicall y significant abnormality on screening electrocardio gram (ECG), including 
but not necessarily limite d to a confirmed QTc (Fridericia correction method)  value ≥  
450 msec for mal es or ≥  470 msec for females.  
22. Stroke within 18 months before  screening, or history of a stroke concomitant wit h 
onset of dementia  
23. History of brain tumor  or other clinically significant space -occupying lesio n on CT or 
MRI  
24. Head traum a with cl inically signif icant loss of consciousness wi thin 12 months before 
screening or concurrent with the onset of dementia  
25. Onset of  dementia secondary  to cardiac arrest, surgery with general anesthesia, or 
resuscitation  
26. Specifi c degenerative CNS diseas e diagnos is other than A D (e.g., Huntington's 
disease,  Creutzfeld -Jacob di sease, Down's syndrome, Frontot emporal Dementia, 
Parkinson's disease)  
Cassava Sciences, Inc. Clini cal Protocol P TI-125-04 
Simufilam (PTI-125), A small mo lecule to treat AD June 1 1, 2021 
Ame ndment  #7    Page 20 of 39   CON FIDENTIA L 27. Wernicke's encephalopathy  
28. Active acute or c hronic CNS infection  
29. Donepezil 23 mg or grea ter QD currently or withi n 3 month s prior to enrollment  
30. Discontinued AChEI <  30 days prior to  enrollment  
31. Antipsychotics; low doses  are allowed only if giv en for sleep disturbances, agitation 
and/or aggressi on, and only if the subject has received a s table dose for at least 3  
month s before enrollment  
32. Tricyclic antidepressants  and monoamine oxidase inhibitors; all other antidepressants 
are allowed only if the subject has received a stable dose for at least 3 months before 
enrollment  
33. Anxiolytics or  sedative-hypnotics, incl uding bar biturates (unle ss given in low doses 
for beni gn tremor); low doses of benzodiazepines and zolpidem are allowed only if 
given f or insomnia/sleep disturbance, and only if the subje ct has received a stable 
dose for at least 3  months before enrollment  
34. Immun osuppr essants, including systemic corticoster oids, if taken in clinically 
immunosuppressive doses (Steroid use for allergy or other inflammation is 
permitted .) 
35. Antiepileptic medi cations if taken f or control of seizures  
36. Chronic intake of opioid -containing a nalges ics 
37. Sedat ing H1 antihistamines  
38. Nicotine  therapy (all dosage forms including a patch), varenicline (Chantix), or 
similar therapeutic agent within 30 days before screening  
39. Clinically significa nt illness within 30  days of enrollment   
40. History of  signific ant ne urologica l, hepatic, renal, endocrine, cardiovascular, 
gastrointestinal, pulmonary, or metabolic disease   
41. Loss of  a sign ificant volume of blood (>  450 mL) within 4 weeks prior to enrollment  
42. COVID -19 infection  within 3  months of screening  
6. STUDY  DRUG  
6.1. STUDY DRUG  PHYSICAL DESCRIPTI ON A ND PREPARATION  
Inves tigational simufilam  and pl acebo will be s upplied by Cassa va Sc iences  as coated 
tablet s in 70- or 20 0-count bottles . Several days of ex tra tablets are included in each 
bottle to all ow flexib ility of scheduling visits . 
Cassava Sciences, Inc. Clini cal Protocol P TI-125-04 
Simufilam (PTI-125), A small mo lecule to treat AD June 1 1, 2021 
Ame ndment  #7    Page 21 of 39   CON FIDENTIA L All remain ing study dru g will be retur ned to  the sponsor or design ee. 
6.1.1.  Storage  
Bottles of study drug  tablets should  be sto red at controlled room tempe rature , 20-
25º C (68 -77º F)  and protected from light and  moisture.  
6.1.2.  Drug Accou ntability 
The Invest igator will be responsib le for monitoring the receipt, storage,  dispensing  
and accounting  of all study  medi catio ns according  to site SO Ps. All invoices  of 
study medicatio n shipments  must  be retained  in the site study file. Accur ate, 
original site records must be mainta ined of drug inventor y and dispensin g. All  
records  must  be made  available  to the sponsor  (or design ee) and appropria te 
regulatory  agencies  upon  request.  
6.2. ADMI NISTRATION  AND DOSING REGIMEN  
Patients  will receiv e 100 mg  simufil am b.i.d. during the  open-label portion s of the 
study and either 100 mg simufilam or matching placebo during the randomiz ed 
withdrawal portion of the study. Simufilam  or placebo  tablets should be at lea st 1 h 
before or after a meal.  
6.3. CONCOM ITANT  MEDICATIONS  
Use of prescripti on or non-prescriptio n medi cations  will be recorded  during  the 
study.  Chronic medicat ions must  be stable for 3 months  at en try. 
7. STUDY  PROCEDU RES 
Appen dix A presents the Schedule  of Activities. 
Prior to any study -related  activiti es, the Inform ed Conse nt Form  (ICF) must  be signed  
and dated by the patient or le gal representative . The format  and content  of the ICF must  
be agreed  upon by the Principal Investigat or(s), the appropriate  IRB and the Sponsor  
(or designee).  The signed and dated ICF must  be retained by  the Investigator  in the 
subject's  file. 
7.1. STOPPI NG CRITERIA  
Liver chemistry thresh old stopping criteria have  been designed to assure  patien t safety 
and to e valuate liver ev ent etiology during adm inistration of S tudy Drug . 
Adminis tration of Study  Drug will be discontinued if a ny of the following liv er 
chemistry stopping criteria oc curs:  
 
Cassava Sciences, Inc. Clini cal Protocol P TI-125-04 
Simufilam (PTI-125), A small mo lecule to treat AD June 1 1, 2021 
Ame ndment  #7    Page 22 of 39   CON FIDENTIA L • ALT or AST ≥ 3 x ULN.  
• ALT or AST  ≥ 2.5 x ULN  and total bilirub in ≥ 2 x ULN .  
• ALT or AST ≥ 2 x ULN  if associated  with appearance or worsening of a ra sh 
or hepatitis sym ptoms (f atigue, na usea, v omiting, right upper qua drant pain or 
tendern ess, fever, rash o r eosino philia).  
• ALT or GGT ≥ 2.5 x ULN  that persists for ≥4 weeks.  
 
In the event of discontinuation due to liv er abnormalities, the patient will be  
appropriately inve stigated  to determine  the potential cause and ref erred to a ph ysician 
experienced in the  treatment of hepatic disorders.  
 
An additional stopping criterion will be  body weight lo ss of ≥ 2 kg resulting in a BMI < 
18.5.  
 
7.2. EVALUATIONS BY VISIT 
7.2.1.  Screening Visit  1 (Days -29 to 0) 
Patients who completed PTI-125-02 < 60 days  of study start  will not be res creened 
but will sign the ICF on Day 1 or ea rlier for this o pen-label extension . 
For all othe r pati ents, the follow ing will be comple ted in the  screening visit : 
• Informed  Consent  
• Review  of Inclusion  and Exclusion  Criteria  
• Medical  history  
• Review  of concomit ant medi cations  
• Confirmation that the patient is either fully vaccinated  for the COVID -19 
virus at least 2 weeks prior to first dose of simufil am, or a positive  serology 
test for the C OVID -19 virus  with no current symptoms  
• If needed, CT scan to confirm I/E cr iteria , per inve stigator jud gement  
• MMSE -2 evaluatio n (prior patients do not need to meet  16 to 26 range)  
• Columbi a Suicid e Severity Rating Scale (C -SSRS)  
• Physical  examination, including  measurement  of vital signs  (blood pressure, 
temperature , pulse and respiratory rate ), height , weight  
• A 12-lead ECG  (5-min supine)  
• Laboratory  assessments,  including  serum  chemistry,  hematolog y, urinalysis , 
and screens for HCV, HIV and H BsAg. 
• Urine drug screen.  
Cassava Sciences, Inc. Clini cal Protocol P TI-125-04 
Simufilam (PTI-125), A small mo lecule to treat AD June 1 1, 2021 
Ame ndment  #7    Page 23 of 39   CON FIDENTIA L 7.2.2.  Screening  Visit 2 (Days -28 to 0) 
This C SF draw is required for all NE W patients  meetin g Screening Visit 1 cr iteria  
who do not have  a prior positive a myloid PE T scan or MRI showi ng hippo campal 
volume loss  OR prior CSF bio markers confir ming AD . If Screen ing Visit 2 and Study 
Day 1 visit are c ombined , the CSF sample  collection will occur 1-3 h after dosing and 
after the MMSE -2, ADAS -Cog11, NPI and GDS  testing  has been com pleted . 
• CSF sample collection  (5 mL)  
• CSF samp les should be he ld at the study  site frozen at  -70°C, pending  
shipping  instructions  from  the Sponsor.  
 
7.2.3.  Study Day 1 (Dosing Initiation)  
Patients will come to the clinic in the mor ning. P rior to dosing , the followin g 
assessments will be cond ucted: 
• Confir mation  of Inclusion/ Exclus ion Criteria  
• Review of concomit ant medic ations 
• Vital signs (b lood pressure, temperature, pulse and respiratory rat e), and 
weight 
• Listen to heart and lungs  
• ADAS -Cog11, NPI, GDS testi ng and C -SSRS  – Since Last Visit vers ion. If 
the C -SSRS indicate s imminent  risk for suicidal ity, defined as the patient 
positively endorsing qu estions 4 or 5 of the s uicidal ideation section or any 
suicidal behavio r questions , discontinue study drug and refer for appro priate 
care. 
• Blood sampl e collection for clinical laboratory tests 
• Plasma samp le coll ection for SavaDx and other  plasma  biomarkers . 
• ECG 
 
Patients  will be adminis tered  100 mg simuf ilam b.i.d.  1-2 h befo re or after  a mea l.  
After dose  on Study Day 1, the following  assessment s will be conducted:  
• Vital signs (b lood press ure, temperat ure, pulse and resp iratory rate) at 
approximately  30 min, and 1 and 2 h post-dose.  
• Adve rse event  monito ring 
 
Clini c personnel  will monitor the patients  for AEs until discharge  from  the clinic. 
Upon invest igator judgment , patients will be disch arged with their supply of study 
Cassava Sciences, Inc. Clini cal Protocol P TI-125-04 
Simufilam (PTI-125), A small mo lecule to treat AD June 1 1, 2021 
Ame ndment  #7    Page 24 of 39   CON FIDENTIA L drug until the next visit. They  will be i nstructed  to take study dru g twice daily, at leas t 
1-2 h before or  after a m eal. A dose can be up to 4 h l ate, but if a dose is missed, the 
next dose should NO T be double d. 
All follo w-up visits c an be +/- five (5) days  for flex ibility. For all follo w-up visits 
except Mon ths 4.5, 7.5 and 10.5 , patients will come to the cl inic in t he m orning and 
will be instructed  NOT  to take their mornin g dose prior  to coming to the clini c.  
7.2.4.  Follow-up Visits on Mon ths 1, 3, 9, 13, 15, 21  
Patients  will return to clinic in the m orning befor e taking th eir morning dose. 
Within 30 min  prior  to dosing,  the following  assessments  will be conducted:  
• Blood sample  collection  for PK assessment (for Cmin – Month 15 only) 
• Clinical laborator y tests (blood and urine ) (All vis its except Month 13 ) 
• Plasma  sample collec tion (from 8 mL whole blood)  for Sava Dx and other  
plasma  biomarkers  (All v isits except Month s 1 and 13) 
 
After dose, the following  assessments  will be conducted: 
• Vital signs ( blood press ure, temperatu re, pul se an d respiratory rate), and 
weight  
• Listen to hear t and lungs  
• ECG (Month 1 only ) 
• Adverse even t monitori ng 
• ADAS -Cog11, NPI, GDS  and C-SSRS  – Since Last Vis it version . If the C -
SSRS indicate s immi nent risk  for suicidal ity, defined as the patient posi tively 
endorsing qu estions 4 or 5 of the s uicidal ideation section o r any suicidal 
behavior  questions , discontinue study drug and refer f or appro priate care . 
• Saliva collection  for genetic testing  (Month  15 Visit only) 
 
7.2.5.  Follow -up Visit on Month  2 
Patien ts will return  to clinic in the m ornin g before taking th eir morning dose. 
Within 30 mi n prior to dosin g, the followin g assessments will be conducted:  
• Clinical laboratory tes ts (blood and urine ) 
 
After dos e, the following assessments  will be condu cted: 
• Vital signs  (blood pressure, temperatu re, pulse and re spiratory r ate), and  
weight   
Cassava Sciences, Inc. Clini cal Protocol P TI-125-04 
Simufilam (PTI-125), A small mo lecule to treat AD June 1 1, 2021 
Ame ndment  #7    Page 25 of 39   CON FIDENTIA L • Listen to heart and lun gs 
• Adverse even t moni toring 
• C-SSRS  – Since Last Visit version . If the C -SSRS indicate s imminent risk for 
suicidal ity, defined as  the patient posi tively endorsing questi ons 4 or 5 of the 
suicidal  ideation section o r any suicidal behavior  questions , discontinue s tudy 
drug and refer for appro priate care. 
 
7.2.6.  Follow -up Visits on Months 4.5, 7.5 and  10.5 
Patients  will return t o clin ic at an y tim e of day . The visit may be conducted by 
telemedicine , based on the judgement of the Investigator . 
The followin g assess ments will be conducted:  
• Vital signs (blood pressure, te mper ature, pulse and r espira tory rate), and 
weight  
• Listen to h eart and l ungs  
• Adverse  event monitoring  
• C-SSRS  – Since Last Visit version . If the C -SSRS indicate s imminen t risk for 
suicidality, defined as t he patient posi tively endorsing questions 4 or 5 of the  
suicida l ideation section o r any suic idal behavior questio ns, discontinue study 
drug and refer for appro priate care . 
 
7.2.7.  Follow -up V isits on Mon th 6 and 18  
Patien ts will return  to the clinic in the mornin g on the Mont h 6 Visit. Those patients 
undergoin g a CSF draw wi ll take their morning  dose upon arrival (time of d osing to  
be reco rded). 
Patie nts will return to clin ic in the mornin g befor e taking th eir morning dose. 
Within 30 mi n prior to dosin g, the follo wing assessments will be conducted:  
• Blood sample  collection  for PK assessment (for Cmin – Mon th 18 only ) 
• Clinical  laboratory tes ts (blood and  urine ) 
• Plasm a sample collec tion (from 8 mL whole blood ) for Sava Dx and other  
plasma biomarkers. 
 
After dose , the following  assessments  will be conducted:  
• Vital signs (blood press ure, temperatu re, p ulse and r espiratory ra te), and 
weight   
• Listen to hear t and lun gs 
Cassava Sciences, Inc. Clini cal Protocol P TI-125-04 
Simufilam (PTI-125), A small mo lecule to treat AD June 1 1, 2021 
Ame ndment  #7    Page 26 of 39   CON FIDENTIA L • Adver se even t monitoring 
• ECG 
• ADA S-Cog1 1, NPI, GDS , and C -SSRS  – Since Last Visit ve rsion. If the C-
SSRS indicate s imminent risk for suicidal ity, defined as the patient posi tively 
endorsing question s 4 or 5 of the s uicidal ideation section o r any suicidal 
behavior questi ons, discontinue s tudy drug and refer for appro priate care . 
• CSF sampl e collection at Month 6  (time post -dose to be recorded)  only for 
the first 25 patients  with a baseline  CSF . (The next 25 patients with a 
baseline CSF will have CSF drawn at Month 12 ). Month 18  CSF draw is 
OPTION AL for patients who provided a Mon th 6 or Mon th 12 CSF  and is not 
an option  for any other patients.  
 
7.2.8.  Month 12  and 24  Follow -up Visit s 
Patien ts will return to clin ic in the mornin g before taking th eir morning dose. Patients 
who we re enrolled prior to this amendment can terminate after completing the  
original 12-month open -label portion  or can re consent  to the randomized withdrawal 
and final  6-month open -label  portion .  Month 12  morning  dose in the clinic will be 
from Op en-Label Period 1 bottle.  Month 12 eve ning do se will be fro m the 
Randomized Period 2 bottle . 
Within 30 mi n prior to dosin g, the followi ng assessments will be conducted:  
• Clinical  laboratory tes ts (blood and urine ) 
• Plasma  sample collec tion (from 8 mL whole blood)  for Sava Dx and other  
plasma  biomarkers . 
 
After dose, the following  asses sments  will be conducted:  
• Full physical exam  
• Adve rse event mo nitoring  
• MMSE -2 
• ECG 
• ADAS -Cog11,  NPI, GDS, and C-SSRS – Since Last Visit version . If the C -
SSRS indicate s imminent risk for suicidal ity, defined  as the patient posi tively 
endorsi ng questions 4 or 5 of the s uicidal ideation section o r any suicidal 
behavior questions , discont inue study dru g and refer for  appropriate car e. 
• CSF sample col lection  at M onth 12 (time post -dose to be recorded)  for 
patients with a screening  CSF who did not provide a CSF  sample at 
Month 6.  For those patients w ho provided  a Month 6 CSF , this Month 12 
CSF will be OPTI ONAL . After 50 patients have provide d either Month 6 
Cassava Sciences, Inc. Clini cal Protocol P TI-125-04 
Simufilam (PTI-125), A small mo lecule to treat AD June 1 1, 2021 
Ame ndment  #7    Page 27 of 39   CON FIDENTIA L or M onth 12  CSF, no additional  patients will have CSF draw n after 
screening . No CSF will be drawn at Month 24 . 
 
For patien ts unde rgoing a CSF draw , CSF sample colle ction (5 mL) will occur 1-3 h 
after dosin g and after the MMSE , ADAS -Cog11,  NPI and GDS  testing has been 
completed . These samp les will be tested for CSF biomark ers.  
 
Patients who compl ete Month  12 prior to a vailabi lity of drug suppl y for the 
randomized w ithdrawal ph ase (Mon ths 12  – 18) will be dispensed additional open -
label simufilam and wil l return for a Withdrawal Day 1 Visit  as appropriate . 
 
7.2.9.  Withdrawal Day 1 Visit – If Needed  
This a dditional  visit is only for patients w ho c omplete Mont h 12 prior to 
availability of  drug supply for the randomized withdrawal phase  (Months  12 – 
18) and who hav e been dispensed additional open -label simufilam while waiting . 
Patients will return to the clinic at any  time of day f or the followin g assessments : 
• ADAS -Cog11, NPI, GDS , and C -SSRS – Since Last Visit version . If the C -
SSRS indicate s imminent risk for suicidality, defined  as the patient posi tively 
endorsing questions 4 or 5 of the s uicidal ideation s ection o r any suicidal 
behavio r questi ons, discontinue  study drug and refer for app ropriate care . 
 
These  patients  will return to the clinic one month later for the Month 13 visit and 
continue with the rest  of the scheduled visits.   
7.3. LABORATORY ASSESSM ENTS 
7.3.1.  Clinical  Laboratory  Tests 
The fo llowing clinical laboratory tests will be performed at screening, Day 1 pre -
dose, and at Months 1,  2, 3, 6, 9, 12, 15, 18, 21 and  24:  
• Hematology :  white  blood  cell (WBC)  count with differen tial, red blood  cell 
(RBC) count, hemoglobin , hematoc rit, platelet count . 
• Serum Chemis try:  glucose,  sodium,  potassium,  chloride, bicarbonate,  
calcium , phosph ate, blood  urea nitrogen  (BUN),  total bilirubin, creatinine,  
cholester ol, triglycerides , albumin , globuli n, total protein, uric acid, alkaline  
phosph atase, alanine transam inase (ALT), aspartate  transaminase  (AST), 
gamma glutamyl  transpeptidase  (GGT ), lactose  dehydro genase (LDH) . 
• Urinalysis : color, specific gravity,  pH, prote in, sugar,  ketone s, occult blood, 
creatinine clearance calcula tion by Co ckcroft -Gault equa tion (witho ut 
requiring a 24-h urine collection) . 
Cassava Sciences, Inc. Clini cal Protocol P TI-125-04 
Simufilam (PTI-125), A small mo lecule to treat AD June 1 1, 2021 
Ame ndment  #7    Page 28 of 39   CON FIDENTIA L  
7.3.2.  Preparat ion of Whole B lood Sample s for Lymphocyte  and Plasma  Biomarke rs 
Whole blood samples  will be collected on Day 1 and Months 3, 6, 9 , 12, 15, 1 8, 21 
and 24 . Blood s amples (8 mL t otal) will be drawn into a Vacutainer®  tube 
conta ining K2EDTA. As advise d by Spons or, the blood may be  spun down to 
separa te the plasm a (all new patients ) OR shippe d as whole bl ood (patients with 
prior  samples shipped as whole blood . These  patients  with prior samples shipped as  
whole b lood will contin ue to have samples shipped as whole blood only through 
Mont h 12. Samples at Months 15 , 18 21 and 24 will be s pun to  plasma ). Plasm a 
should be froze n at -70°C and held unti l advised  by the S ponsor to ship to: Dr. John 
Xu, Abil ene Christian U niversity, HAL R esearch Center Room 201, 1 201 East 
Ambler Ave , Abil ene, TX 79699. Whole blood  should be shipped immediately a t 4°C 
to: Dr. Hoau -Yan Wang,  CUNY School of Medic ine, SOM CD I 3370,  85 St. Nicolas 
Terrace, N ew York, NY 10027, or another lab.  Do not ship sample s on Frid ay.  
7.3.3.  Prepara tion of Plasma Samples  for Pharma cokine tic Determination  
At each blood  collection  for PK (pre-dose samples for Cmin at Months 15 and 18 
only, blood samples (4 mL) will be drawn into a Vacutainer® tube containing  
K2EDTA. The tubes will be placed  on ice. With in 30 min of collec tion, the blood  
will be centr ifuged at approximate ly 1000 X G for 15 min between  4-5°C. Within 
30 min of centrifuging , plasma (at least 1.5 mL) will be split into two aliquots, 
transfe rred to polypropylene  tubes and stored at -20°C  or below u ntil analys is.  
At the end of the study, PK sampl es will be shipped  frozen on dry ice to: 
Worldwid e Clinic al Trials Bio analytical S ciences , 8609 Cross Park Drive, Austi n, 
TX 78754 for bioanal ytical  analysis of simufilam  with a validat ed ass ay. The secon d 
set of samples  will be s hipped separat ely on ce recei pt of the fir st set is  confirmed.  
  
7.3.4.  Preparation o f CSF samples 
CSF will be coll ected  and aliquot ed into 5 ml S crew-Cap LoBind Eppendorf® tubes 
(# 0030122356 ). CSF sample s should be s plit int o two aliqu ots of 2. 5 mL. Samples 
will be held frozen at  -70°C.  
When noti fied by Sponsor , samp les will be shipped to Dr. Wang  at CU NY (address 
above)  for biomarker  analyses or anothe r lab. Samples will be shipped frozen on dry 
ice (Mon – Wed ). 
7.3.5.  Collection of Cheek Sw ab Saliva  Samples for Genetic Testing  
Saliva samples wil l be collect ed only at Month  15. Patients will refrain from eating  or 
drink ing 1 h prior to saliva colle ction. Ea ch patient will be instructed to spit into a 
saliva collection tube . The sa liva will be stored at -20°C until instructed to sh ip by the 
Sponsor.  
Cassava Sciences, Inc. Clini cal Protocol P TI-125-04 
Simufilam (PTI-125), A small mo lecule to treat AD June 1 1, 2021 
Ame ndment  #7    Page 29 of 39   CON FIDENTIA L 8. EARLY  DISCONTINUA TION  
Patients may choose to discon tinue study  drug or study participation at any time, for 
any reason, and without  prejudic e. Patie nts who d iscontinue may be replaced at Sponsor 
discret ion. 
 
The follo wing must  be completed  and documen ted in the source documents  and CRFs  
for all patients who discontinue  the study early:  
• The reaso n for early  study  discontin uation. 
• Vital signs (blood pres sure, te mperature, pulse and res piratory rate ), weight, full 
physica l examina tion, clinical laborat ory tests, ECG , use of concomitant  
medications,  and advers e events)  should be obtain ed at discharge  prior t o release. 
• Collection of pla sma for b iomarkers   
• MMS E-2 
• ADAS -Cog11, NPI and GDS  (If the pat ient scor es above 4 on the G DS assess ment, 
a referral for further f ollow -up with the patient ’s primary care p hysician or 
psychiatr ist is required. In addition, immedia tely ad minister the C-SSRS . If the C -
SSRS indicate s imminent risk for suicidal ity, define d as the patient pos itively 
endorsing  questions 4 or  5 of the s uicidal id eation section o r any suicidal behavior 
questions , immedi ately contact the s ponsor.) 
9. ADV ERSE EVENTS/SERI OUS ADVER SE EVE NTS  
9.1. ADVERSE  EVENTS  - DEFINITION  
An adverse  event  (AE) is any unde sirable  event that occurs  to a subject  during a 
study, whet her or not that event is consi dered study  drug-related.  Monitor ing for AEs 
will start at dosi ng. Examples include:  
• Any treatm ent-emergent signs  and symptoms (events  that are marked  by a 
change from  the subjec t's baseline/en try status  [e.g.,  an increase in severity or 
frequency of pre-existing  abno rmality  or disorder])  
• All reactions  from  study  drug, an overdose, abuse  of drug, withdraw al 
phenomena,  sensitivity or toxici ty to study drug 
• Apparently unrelated  illnesses  
• Injury or accidents  (Note:  if a medical condition is known to have  cause d the 
injury  or accident,  the medical condition  and the acciden t should be reported  as 
two separate medical events  [e.g., for a fall secondary  to dizzine ss, both 
"dizziness"  and "fall"  should  be recorded  separa tely]) 
• Extension s or exacerbations of symptoms , subjective  subject -reported events, 
Cassava Sciences, Inc. Clini cal Protocol P TI-125-04 
Simufilam (PTI-125), A small mo lecule to treat AD June 1 1, 2021 
Ame ndment  #7    Page 30 of 39   CON FIDENTIA L new clinically  significan t abnormalities in clinical laboratory , physiological  
testing or physical  examina tion 
 
All AEs, whether or not related to the study drug, must  be fully and complet ely 
docum ented on the AE page  of the elect ronic Case Report Form (eCRF)  and in the 
subject's  clinical chart. 
In the event that a subject is withdra wn from the study because  of an AE, it must be 
recorded  on the eCRF  as such. The subject  shou ld be followed and treate d by the 
Investigator  until the abnormal  param eter or symptom  has resolved  or stabil ized. 
The Investigator  must report all directly observ ed AEs and all spontaneousl y 
reporte d AEs. The Investigator  will ask the subject a non-specif ic question (e.g., 
"Have  you noticed anything  different  since your dose of the study medication?")  to 
assess  whether any AEs have  been experi enced  since the last assessm ent. AEs will 
be identified  and documented on the eCRF in appropri ate medic al termino logy. The 
severity and the relationship to the study drug will be determined  and reported  on the 
CRF  (see bel ow). 
9.2. ADVERSE EVENTS - SEVERITY RATING 
The severity of each AE should be character ized and then classified into one of three 
clearly defin ed categor ies as follows: 
• Mild - the AE does not interfere  in a signif icant manner with the subject's  
normal functionin g level. It may be an annoyance.  
• Moderate - the AE produces  some impai rment  of functioning  but is not 
hazardous  to health.  It is uncomfor table  or an embarrassment. 
• Severe - the AE produces signif icant impair ment of functioning  or 
incapacitation  and is a definite hazard to the subject's health. 
These three categories  are based on the Investigator 's clinical judgment,  which in turn 
depen ds on considera tion of various factors such as the subject's  report, and the 
physic ian's observ ations. The severity  of the AE should be recorded  in the 
approp riate section of the Adverse  Event CRF. 
9.3. ADVERS E  EVENTS   -  RELATIONSH IP TO  STUD Y   DRUG 
The relations hip of each AE to the study drug will be classified into one of three  
defined  categories  as follows:  
• Unlikely  - a causa l relationship between  the AE and the study drug is unlikely.  
• Possible  - a causal  relations hip between the AE and the study drug is possi ble. 
Cassava Sciences, Inc. Clini cal Protocol P TI-125-04 
Simufilam (PTI-125), A small mo lecule to treat AD June 1 1, 2021 
Ame ndment  #7    Page 31 of 39   CON FIDENTIA L • Proba ble - a causal relationship  between the AE and the study  drug is probable. 
For example, the AE is a common  adverse  event known  to occu r with the 
pharma cological class the study drug belongs  to; or the AE abated on study  
drug discon tinuation and reappeared  upon re-challenge  with the study drug. 
These  three categorie s are based on the Investigator's  clinical  judgmen t and 
considerat ion of various factors  such as the subject' s report, the timing of the AE in 
relationship to study  drug admin istration/discontinu ation,  the Investig ator's 
observations and the Investigator 's prior experience.  The relationshi p of the AE to the 
study drug will be recorded in the eCRF. 
9.4. SERIOUS ADVERS E EVENTS AND UNEXPECTED ADVERSE EVENTS - DEFINITIONS  
A Serious Adverse Ev ent ( SAE)  includes  (but is not limited to) an experience 
occurr ing at any dose that results  in any of the following  outcom es: 
• Death 
• A life-threatenin g event  (i.e., the subject is at imme diate risk of death  from  the 
reaction as it occur s). "Life -threatening " does not include  an event that, had it 
occurred in a more  serious form,  might have caused  death. For example,  drug-  
induced hepatitis that resolved  without  evidence  of hepatic  failure would not be 
considered  life-threatening even  though drug-induced  hepa titis can be fatal.  
• In-patient hospitalization (hospital admiss ion, not an emergenc y room  visit)  or 
prolon gation of  existi ng hosp italization. 
• A persi stent or signific ant disability/in capacity (i.e., a substantial  disruption of 
the subject's ability  to carry out normal  life functions). 
• A congeni tal anomaly/birth defect . 
 
In additi on, medi cal and scien tific judgment should  be exercise d in deciding whethe r 
other  situation s should be consi dered an SAE  (i.e., important  medical events that may 
not be immediately  life-threatening  or result in death but may jeopardize the subject 
or may require medical  or surgical intervention  to prevent one of the other outcom es 
listed  in the definition above) . Examples of such medical  event s include (but are not 
limited  to): allergic bronchospasm  requiring intensive treatment in an emergency  
room or at home, blood dyscrasias  or convul sions  that do not resul t in in-patient 
hosp italizati on, or the development  of drug depende ncy or drug abuse.  
An unexpected AE is one for which  the specificity or severity  is not consistent with the 
current Investi gator's Broc hure. For example,  hepatic necrosis would  be unexpecte d (by 
virtue of greater sever ity) if the Investigator' s Brochure only listed  elevated  hepatic 
enzymes  or hepatitis.  
Cassava Sciences, Inc. Clini cal Protocol P TI-125-04 
Simufilam (PTI-125), A small mo lecule to treat AD June 1 1, 2021 
Ame ndment  #7    Page 32 of 39   CON FIDENTIA L Similarly,  cereb ral thromboembo lism an d cerebral vasculitis would be unexp ected 
(by virtue of greater  speci ficity) if the Investigato r's Brochure only listed  cerebral 
vascular  accidents. 
9.5. SERIOUS  ADVERSE EVEN TS REPORTING  
The reporting of SAEs  by the Sponsor  to Regulat ory Authorities  (e.g., FDA)  is a 
regula tory requirement. 
 
All SAEs must  be reported  immediatel y (within 24 h of learning  of the event) by 
telephone  or notification via  email  through the EDC system  to: 
 
Nadav Friedmann , PhD, MD  
Cassava S ciences, Inc.  
Email:  nfrie dmann@ cassavasciences .com  
Phone:    925-788-4585  
 
Do not delay reporting a suspected  SAE  to obtain additio nal informat ion. Any 
addition al information,  if collec ted, can be reported to the Spon sor as a follow -up 
to the initial  report. 
 
A completed SAE  repor t form must be sent within  five (5) working  days to the 
medical monitor. The Sponsor w ill report SAEs to the IRB  and FD A as req uired . 
 
In the case of a death  or other SAE  that has occurred withi n 30 days after 
receiving study  drug,  the Principa l Investigator must also report such an event 
within  24 hours of being notif ied.  
 
In the event of  any SAE (other than death), the subject will be instructed  to conta ct 
the study physician (P rincipal Investigator or designee)  using the phone  number 
provided in the ICF. All patients experiencing  an SAE  will be seen by a Princ ipal 
Investigator or designee  as soon as feasibl e following  the report  of an SAE. 
10. STATI STICAL  CONSIDERATI ONS  
10.1. ANALY SIS POPULATION S 
All patients who receive  study medication  will be include d in safety analy ses. All 
patients  who have sufficient da ta for biomarker, ADAS-Cog1 1, NPI and GDS  analyses 
will be i ncluded i n the analysis  popula tion for each measure indiv idually .  
Cassava Sciences, Inc. Clini cal Protocol P TI-125-04 
Simufilam (PTI-125), A small mo lecule to treat AD June 1 1, 2021 
Ame ndment  #7    Page 33 of 39   CON FIDENTIA L 10.2. PHARMA COKINET IC PARA METERS 
The only plasma  PK parameters t o be collected  from th is study are the Cmin values from 
blood sam ples t aken prior t o dosing  at Months 15 and 18.  
 
10.3. STATISTICAL ANALYSIS  
Biomarker endpoints to be analyzed  include : 1) CSF Aβ42, 2) CSF total tau 3) CSF p -
tau181, 4) CSF neur ofilament light chain, 5) CSF neurogranin, 6) CSF sTREM2 , 7) 
plasma neurofilam ent li ght chain, 8) plasma ne urogranin , 9) plasma total tau, 10) 
plasma Aβ42, 11) Sava Dx lymphocyte as say, 12) Sava Dx plasma ass ay and 13) mTOR 
assay . These da ta wil l be a nalyzed b y paired t test  comparing baseline t o Month 6 or 
Month 12. Other appro priate  statistics may be perfo rmed to compar e mild versus 
moderate patients . 
 
The ADAS -Cog11, NPI an d GD S endpoin ts will be an alyzed  by linear regre ssion with 
pre-planned compar isons of mild versus moderate patients . Other appropria te statist ics 
may be performed . 
 
Month 12 to Month 18 ADAS -Cog11, NPI an d GD S data will be analyzed by mixed 
model repea ted measures (MMRM) analys is. Month 6/ 12 to Month 18 CSF biomarker 
data wil l be analyzed b y ANCOVA for the effe ct of treatment with Month 6/12 value 
as the covariate , or by ANOVA .  
 
10.4. SAFET Y ANAL YSIS 
Adve rse event s reported  on case report forms will be mapp ed to preferre d terms and 
organ  systems  using  the MedDRA  mapping  system. Vital signs  and clinical 
laboratory results will be descr iptively  summariz ed in terms  of change  from  
screen ing values. 
10.5. SAMPLE SIZE 
Up to 200  patients may be enrolled in this study. Eligi ble patients  include those who 
complete d PTI-125-03 and PTI -125-02 as  well as  new patien ts. 
11. STUDY TERMINATIO N 
The study  will be termin ated following  complet ion of the study or at any time at the 
discretion  of the Sponsor.  
Cassava Sciences, Inc. Clini cal Protocol P TI-125-04 
Simufilam (PTI-125), A small mo lecule to treat AD June 1 1, 2021 
Ame ndment  #7    Page 34 of 39   CON FIDENTIA L 12. DATA  COLLECTION,  RETENTION  AND  MONITORING  
12.1. CASE  REPO RT FORMS 
Elect ronic case report forms (eCRF s) will be used for each subje ct. The patients  in the 
study  will not be identified  by name  on any study  documents to be colle cted by the 
Sponsor  (or CRO designee)  but will be identified  by a unique patient number.  
All clinical information request ed in this protocol will be recorded in the eCRFs  
provided  by CSI. In case of  error , the correction will b e noted , initialed and dated.  
eCRFs must be reviewed  and verified for accuracy  by the Principal  Investigator  and 
signed-off before collection by the Sponsor (or CRO designee).  Paper source 
documents, if  used,  will remain  at the Invest igator's  site after study  complet ion. 
12.2. AVAILABILITY AND  RETENTION  OF INVEST IGATIO NAL RECORDS  
The Investigator  must  make  study  data accessible to the monitor , other authorized  
represe ntatives of the Sponsor (or designee)  and Regulat ory Agency  (e.g.,  FDA) 
inspectors  upon  request.  To assure accuracy of data collected in the eCRFs, it is 
mandato ry that Sponsor  representatives  have access  to origin al source docume nts 
(e.g., subject  records , subjec t charts,  and laborator y reports).  During  review  of these  
documents , the subject' s anonymity  will be maintained with adherence to 
profes siona l standards  of confi dentiality  and applicable  laws.  A file for each subject 
must  be maintained that include s the signed  ICF and all source  documentation  
related to that subject. The Investigator  must ensure  the reliability and availa bility of 
source documents  for the eCRF.  
Investigators  are requir ed to maint ain all study docu mentation  until notificatio n by 
CSI that any records  may be discard ed. 
The Investi gator is responsibl e for main taining  adequate  case histories in each 
subject's  source records.  
12.3. SUBJECT CONFI DENTIALITY  
All reports  and subject  samples  will be identif ied only by the a ssigned patient n umbe r 
and in itials to mainta in subject  confidentiality.  Additional  subject  confidentiality  
issues  (if applicab le) are covered in the Clinical Trial Agre ement.  
Cassava Sciences, Inc. Clini cal Protocol P TI-125-04 
Simufilam (PTI-125), A small mo lecule to treat AD June 1 1, 2021 
Ame ndment  #7    Page 35 of 39   CON FIDENTIA L 12.4. LIABILITY  
In the event of a side effect  or injury,  approp riate medical care as determined by the 
Investigator  or his/her  designated alternate will be provided.  
If a bodily  injur y is sustained, resu lting directly fr om the use of the study drug, the 
Sponsor  will reimburse  for reasonable  physician  fees and medical expens es necessary 
for treatm ent of only the bodily  injury which  is not covered  by the subject' s medical  or 
hospit al insurance,  provided  that the injury is not due to a neglig ent or wron gful act or 
omission  by the study doctor  and his/her  staff. No other compensation  of any type will 
be provided  by the Spon sor. Compensatio n for lost wages, disabilit y or discomfort  due 
to the study  is not avail able. 
12.5. ETHIC AL AND  LEGAL ISSUES  
The Investigator and site personnel  are respo nsible for conducting  this study  in 
accordance  with the ICH,  GCP, and all other  applicable  laws and regulati ons. 
12.5.1.  Institu tional  Review  Board 
The protocol  and Informed  Consent  Form  must be approved  by an IRB before  the 
study is initiated. The IRB must  comply  with U.S. CFR 21 Part 56 and local  laws. 
Docu mentation of IRB approval must be provided to the Sponsor.  Investigators  are 
responsible  for the following:  
• Obtain ing IRB approval  of the protoco l, Informed Consent  Form , and any 
advertisements  to recruit  patie nts and IRB approval  of any protoco l 
amendment s and Informed  Consent Form revisi ons before  implementing  the 
changes . 
• Providing  the IRB with any required  informa tion before  or durin g the study . 
• Subm itting progress  reports  to the IRB,  as required,  requesting  additional  
review  and approval,  as need ed; and providing copie s of all relevant  IRB 
communi cations to the Sponsor. 
• Notifying the IRB within 15 calendar  days of all SAEs  and unexpe cted AEs 
related  to study medicatio ns reported by the Spons or to the Investi gator. 
Cassava Sciences, Inc. Clini cal Protocol P TI-125-04 
Simufilam (PTI-125), A small mo lecule to treat AD June 1 1, 2021 
Ame ndment  #7    Page 36 of 39   CON FIDENTIA L 12.6. INFORMED CONSENT FORM  
The Sponsor  (or designee)  must review the Investiga tor's propos ed ICF prior  to IRB 
submissi on for approval . An IRB-approved  copy of the Informed  Consent  Form  is 
forward ed to the Sponsor . 
The ICF docu ments  study -specific inform ation the Investiga tor provid es to the subjec t 
and the subject's  agreement to participate.  The Investigator  explains in plain terms  the 
nature  of the study  along  with the aims,  methods,  antic ipated  benefits, potentia l risks, 
and any discomf ort that partici pation may entail.  The ICF must  be signed  and dated 
before the subject enters the study.  The original  ICF and any amended  ICF, signed and 
dated , must  be retained  in the subject's  file at the study site and a copy  must be given to 
the subject. 
13.  INVESTIGATOR RESPONSIBILITIES  
The Investigator  agrees  to: 
• Conduct the study  in accordance with the protocol, except  to protect the safety, 
rights, or welfa re of patient s. 
• Personally conduct  or supervise  the study. 
• Ensure that require ments fo r obtaini ng inform ed consent  comply  with ICH,  CFR 
21 Parts  50 and 56 and local laws. 
• Report to the Sponsor  any AEs that occur during  the study in accordance  with 
ICH, CFR 21 Part 312.64 and local  laws. 
• Read and unders tand the Investigator's Brochure  including potenti al risks  and side 
effects  of the drug. 
• Ensure  that all associat es, colle agues, and employees assisting  in the conduc t of 
the study are informed  about  their obligations  in meeting the abov e commitmen ts. 
• Main tain adequate records in accorda nce with ICH,  21 CFR Part 312.62,  and 
local  laws and have  records  availabl e for inspection  by the Sponso r, FDA, or 
other  author ized agency . 
• Promptly report to the Sponsor  all changes  in research activit y and unanticipated  
problems  involving risks  to patien ts or others (including amendm ents and 
expedite d safety  reports) . 
• Comply  with all other requiremen ts regarding obligations  of Clinical Investig ators 
and all other pertine nt requirements  listed in ICH,  21 CFR Part 312 and local  
laws.  
Cassava Sciences, Inc. Clini cal Protocol P TI-125-04 
Simufilam (PTI-125), A small mo lecule to treat AD June 1 1, 2021 
Ame ndment  #7    Page 37 of 39   CON FIDENTIA L 14. REFER ENCES  
1. Wang H -Y, Pei Z, K. -C. Le e K-C, et al. PTI -125 Reduces Biomarkers of Alzheimer ’s Disea se 
in Patients. J  Prevent Alz heimer's Disease  2020; doi:10.14283. 
2. Burns LH, Wang H -Y. Altered filamin A enab les amyloid beta -induce d tau 
hyperphospho rylati on and neuroinflammation in Alzheimer ’s disease. Neuroimmunol 
Neuroinflammation 2 017;4:263 -71. 
3. Wang H -Y, Lee K -C, Pei Z, Kha n A, Bakshi K, B urns L. PTI -125 binds and r everses an altered 
confor mation of fila min A to reduce A lzheim er's disease patho genesi s. Neur obiol Aging 
2017;55:99 -114. 
4. Wang H -Y, Bakshi K, Frankfurt M, et al. Red ucing amy loid-related A lzheimer’s disease 
pathogenesis by a sm all molecule  targeting fila min A. J Neurosci 2012;32 :9773 -84. 
5. Hansson O, Seibyl J, Sto mrud E, et al. CSF  bioma rkers o f Alzheimer’s disease concord with 
amyloid -β PETand predict clinical progr ession: A  study o f fully automated  immunoassay s in 
BioFINDER a nd ADNI coho rts. Alzheimer' s Dement 2018;14:1470 -81. 
 
Cassava Sciences, Inc. Clini cal Protocol P TI-125-04 
Simufilam (PTI-125), A small mo lecule to treat AD June 1 1, 2021 
Ame ndment  #7    Page 38 of 39   CON FIDENTIA L 15. APPENDI X A 
Events Schedule  
PROCED URE Screen 
Visit 1  Scree n 
Visit  2 DAY 
1 Mon th 
1 Month s  
2, 4.5, 7.5 
& 10.5 Mont hs  
3, 9, 15 
& 21   Month 
13 Month s 
6 & 18  Month 
12 & 
24  ( With-
drawal  
Day 1  ) 
Informed  
Consent a X        (X)   
Medical  
histo ries X          
ECG  X  X X    X X  
CT scan  (X)          
Vital signs d X  X X (X) X X X X  
Physical 
examina tion X  * * (*) * * * X  
Biochemistr y, 
hematology, 
urinalysis  X  
X X Mont h 2 
only X  
X X  
MMSE -2 X        X  
Saliva 
collected  for 
genetic test ing   
   Month 
15 only   
   
HCV,  HBsAg 
& HIV screen  X          
Urine drug 
screen X          
Drug 
dispensation    X X X X  X Xe X 
Pre-dose b lood 
samp le for PK    
   Month 
15 only   Month 
18 
only    
Adverse 
events   X X X X X X X  
Blood draw  
for biomarkers    X   X  X X  
CSF draw   (X) b      (X) c (X) c  
ADAS -Cog, 
NPI and GDS     X X  X X X X X 
C-SSRS  X  X X X X X X X X 
(  ) indicates  performed per inve stigator jud gement or not for all patients    
* Listen  to he art and lungs  
a   Patients who did not ini tially consent for a 2 -year stud y should be reconsented at their n ext study visit.  
b Patients who have a prior amyloid P ET or other  confirmation of  AD can b ypass this baseline CSF draw  
Cassava Sciences, Inc. Clini cal Protocol P TI-125-04 
Simufilam (PTI-125), A small mo lecule to treat AD June 1 1, 2021 
Ame ndment  #7    Page 39 of 39   CON FIDENTIA L c Only for patients with a baseline CSF. Patients with a baseline CSF have the option to do a Month 6 or 12 CSF dr aw. Month 18 CSF 
draw is an option  only for patients who pr ovided Month 6 or 12 CSF.  
d Include weight for BMI  calculation  
e Drug dispensation on ly at Month 1 2 
NB: Withdrawal Day 1 is only for patients who complete Mon th 12 prior to drug supply avail ability for the randomiz ed wi thdrawal . 